Effects omega-3 fatty acid supplementation in the treatment of diabetes

Effects of omega-3 fatty acid supplementation on inflammatory markers and advanced glycation end products in diabetic nephropaty patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201504095623N41

Enrollment

Registered

2015-04-10

Start date

2015-04-16

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+)

Interventions

Intervention 1: Intervention group: Omega-3 fatty acid pearl, 1000 mg, daily, for 12 weeks orally. Intervention 2: Control group: Placebo pearl, daily, for 12 weeks orally.

Eligibility

Sex/Gender

All

Age

45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with diabetic nephropathy with FPG = 126 mg/dl less than 15 years of their disease aged 45 to 85 years.

Exclusion criteria

Exclusion criteria: The intake of omega-3 fatty acid supplements within the past 3 months Uncontrolled diabetes mellitus Current use of warfarin Malignancy Liver cirrhosis Smoking

Design outcomes

Primary

Measure	Time frame
Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Receptor of Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Receptor of Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Fluorometeric method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026